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 Abstract. Neural stem cell transplantation is a promising new
treatment of ischemic or traumatic brain injury. We have now
investigated the involvement of the peroxynitrite - poly(ADP-
ribose) polymerase (ONOO- - PARP) activation cascade in
brain trauma and neural stem cell transplantation. The forelimb
motor cortex of adult male rats was exposed to cold lesion
(-60˚C) and motor function was monitored. Neural stem cells
isolated from E14 rat embryos were labeled with brome deoxy-
uridine (BrDU) and injected into the injured cortex 6 days after
the lesion. After another 6 days, the survival and differentiation
of the grafted cells were investigated with immunohisto-
chemistry. Increased production of ONOO- revealed by
tyrosine nitration was seen in the lesion 2 days after trans-
plantation. Animals treated with the ONOO- decomposition
catalyst FP15 or the PARP inhibitor PJ34 had a significantly
improved motor score, when compared to vehicle-treated
controls. The neurological score further improved following
stem cell grafting in the PJ34 treated, but not in the control
animals. Six days after transplantation, differentiated BrDU
positive cells were found in the cortical penumbra. The
majority of these differentiated cells expressed an astrocyte
marker and some of the cells expressed oligodendrocyte or
neuronal markers. The number of surviving transplanted cells
was significantly higher in the PJ34 treated group. Inhibition
of the ONOO- - PARP activation cascade significantly
improves the effectiveness of neural stem cell transplantation
and promotes rapid functional recovery.
Introduction
Stem cell transplantation is an emerging approach for the
treatment of various diseases of the central nervous system.
Naturally occurring stem cells can be found in the sub-
ventricular and hippocampal subgranular zones (1) and these
cells respond to brain damage by proliferation and migration
to the area of the injury (2,3). The number of these endogenous
stem cells is very limited. Therefore, grafting of exogenous
stem cells may accelerate the natural regeneration process.
Recent findings indicated that neural stem cell transplantation
can be a viable approach for the treatment of brain trauma (4-6)
or stroke (7-10). However, it is still not completely understood
how these cells, endogenous or exogenous, are involved in
the brain repair process (11).
Human trials with various neural stem cell transplantation
strategies ended with both promising results and serious
concerns (12-14). One major limitation of current approaches
is the low number of surviving grafted cells (12,15). Thus, in
most cases the survival rate of the cells is below 10% and this
situation places severe constraints on ultimate beneficial results.
Marginal improvements in cell survival can be achieved by
limiting apoptosis (16,17), free radical production (18), or lipid
peroxidation (19,20). Another approach for increasing the
survival of grafted cells is the application of exogenous growth
factors like GDNF (21,22) or bFGF (23-25). None of these
methods can ensure the complete survival of the graft.
The constitutive nitric oxide (NO) production in the brain
is responsible for the maintenance of cerebral blood flow (26)
and for vasodilatory responses during various physiological
situations. Additionally, NO has been shown to be an important
protective factor during ischemia because of the effects on
blood flow (27). However, excessive neuronal NO production
during ischemia has been shown to be harmful for the tissues
(28). In contrast to its direct vasodilator effect, the damaging
properties of NO are mainly mediated by peroxynitrite
(ONOO-), its reaction product with superoxide. This reactive
oxidant damages DNA by inducing single strand breaks, which
activates the repair enzyme poly(ADP-ribose) polymerase
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(PARP). The over-activation of PARP rapidly utilizes the
available cellular NAD+ and ATP stores. This results in a fast
depletion of cellular energy pools, which ultimately leads to
necrotic cell death (29). Inhibition of this cascade by an
ONOO- decomposition catalyst or a PARP inhibitor has been
shown to be an effective therapy in stroke (30,31) and brain
trauma (32,33). Pharmacological inhibition of PARP
activation may also be a viable approach for improving the
outcome of stem cell transplantation by two ways. First, it
may make the host tissue environment more receptive for a
graft; and second, it may directly protect the transplanted
cells from ONOO- induced necrosis.
The aim of the present study was to investigate the
involvement of the PARP cascade in experimental brain trauma
and neural stem cell transplantation. First, neurological function
and lesion volume were measured in rats after cold lesion of the
forelimb motor cortex treated with an ONOO- decomposition
catalyst or a PARP inhibitor. Second, embryonic neural stem
cell transplantation was applied after cold lesion. Tyrosine
nitration, a footprint of peroxynitrite was measured. In addition,
the effectiveness of the treatments on graft survival and neuro-
logical improvement was tested. Finally, we investigated the
fate of the transplanted cells using immunohistochemistry
and fluorescent confocal microscopy.
Materials and methods
All procedures were approved by the Animal Care and Use
Committee of Wake Forest University School of Medicine.
Surgical procedures were performed in aseptic conditions and
the animals were regularly monitored for signs of inflammation
or distress.
Brain trauma model. The cold lesion protocol was chosen to
induce experimental brain trauma (34,35). Adult male Wistar
rats were anesthetized with halothane and the head was fixed
in a stereotaxic frame with atraumatic earplugs. The scalp was
incised and a circular craniectomy was made over the left
motor cortex; special care was taken to keep the dura intact.
A nickel coated brass stamp with a footprint of 3 mm in
diameter was precooled to -60˚C with a mixture of dry ice
and acetone and was lowered by a micromanipulator to touch
the exposed dura for 3 min. Following the lesion the wound
was closed by surgical suture and the animal regained
consciousness.
Lesion volume was evaluated 6 days after surgery. The
animals were overanesthetized by sodium thiopenthal (100 mg/
kg i.p.) and decapitated. The brain was removed and sliced to
1 mm thick sections and immersed in 1% 2,3,5 triphenyl
tetrazolium chloride (TTC) solution for 20 min followed by
formalin fixation. The slices were scanned and the lesion
volume was determined using Adobe Photoshop software.
Donor cell preparation. Timed pregnant E13 Wistar rats were
given a single i.p. injection of 50 mg/kg brome deoxy uridine
(BrDU) to label the dividing cells. The animal was anesthetized
with sodium thiopenthal 24 h later and the embryos were
excised and put in ice-cold Dulbecco's modified Eagle medium
(DMEM). One embryo was fixed with formalin to check the
effectiveness of BrDU labeling and the others were processed
for the donor cell preparation. The embryos' brain cortices were
isolated under a stereotaxic microscope and digested with
0.1% trypsin and 0.04% DNAse for 1 h at 37˚C. The sample
was triturated with hypodermic needles in DMEM containing
0.04% DNAse to get a suspension of single cells and small
clumps. Cell viability was measured with the trypan-blue
exclusion method. The total cell number was also calculated
in each case using a cell counting chamber. The cell suspension
was kept on ice until grafting (<4 h).
Transplantation procedure. The animals received freshly
isolated neural stem cell grafts 6 days after the cold lesion. We
waited six days because it has been shown previously that
edema formation is not present at this time (36). The dura
mater was exposed under halothane anesthesia and 3 deposits
of 3 µl cell suspension were injected into the penumbra of
the lesion with a Hamilton syringe equipped with a side-hole
needle. Each cell graft was given 1 mm deep into the brain
and contained approximately 50,000 cells/µl. The wound was
closed and the animals were returned to their cages.
Neurological scoring. The animals suffered an isolated cortical
lesion of the right forelimb motor cortex and were tested 1 day
after cold lesion, 6 days later just before transplantation, and
1 and 6 days after transplantation. No other motor deficit was
detectable and the animals had a normal behavior. Neurological
scoring was performed using the rat stroke motor score (37)
with modifications to specifically measure forelimb function
(Table I). Both evoked and spontaneous movements were
tested and the scoring was performed by the same observer in
a blinded fashion.
Treatment groups. Animals were randomly assigned to three
treatment groups: untreated control or treated with the ONOO-
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Table I. Rat forelimb motor score.a
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Held by the tail 1 2 3
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Symmetry of movements Twists (L) Fails to twist (R) Symmetrical movements
Forelimb flexion angle ≈90˚ >90˚ Complete extension
Walking L moves slightly L outstretches <R Symmetrical response
Climbing the cage Fails to climb Left side weak Normal
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aThe combined score is the sum of each individual tests. Higher numbers represent better performance.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
decomposition catalyst FP15 (10 mg/kg/day, i.p.) (33,38) or
the PARP inhibitor PJ34 (10 mg/kg/day, i.p.) (30,39). The
first dose was given immediately following cold lesion and
was administered once daily afterwards. To test the effect of
the treatments on lesion volume the protocol was dis-
continued on the 6th day after lesion, at the intended time of
grafting. The brains were removed and stained with TTC to
evaluate lesion volume. To test the effect of the treatments on
graft survival the animals received transplants 6 days after
cold lesion and were sacrificed a further 6 days later. The
brains were removed, fixed in 10% buffered formalin, and
paraffin-embedded sections were prepared.
Immunohistochemistry. For evaluation of graft survival and
differentiation 5 µm thick sections were prepared and every
50th section was mounted on slides.
The sections were deparaffinized and the BrDU antigen
was exposed using the Retrievagen kit (BD Pharmingen, San
Diego, CA). The sections were incubated with a 1:10 dilution
of biotinylated anti-BrDU antibody (BD Pharmingen) for 3 h
at 20˚C (40). Secondary labeling was achieved by Alexa
Fluor 488 conjugated streptavidin (Molecular Probes,
Eugene, OR).
Cell line specific markers were used to identify
differentiated cells. Anti-glial fibrillary acidic protein (GFAP)
mouse monoclonal antibody (Chemicon, Temecula, CA) was
used to stain astrocytes (1 µg/ml, 1 h, 20˚C), secondary
labeling was achieved by a red-fluorescent Zenon kit
(Molecular Probes). Anti-myelin basic protein (MBP) mouse
monoclonal antibody (Chemicon) was used to identify oligo-
dendrocytes (1:100 dilution, 1 h, 20˚C). Anti-neurofilament 68
rabbit polyclonal antibody (Chemicon) was used to identify
neurons (1:100 dilution, overnight, 4˚C). Alexa-Fluor 546
conjugated goat IgG (Molecular Probes) was used as the
secondary antibody. Staining with the anti-BrDU antibody
always followed the lineage specific labeling (see above).
The sections were visualized by confocal scanning
fluorescent microscopy (Zeiss Axiovert 100M). Three-
dimensional visualization of the cells was achieved by
stepwise scanning of 1 µm thick optical sections and soft-
ware reconstitution. This procedure allowed us to determine
whether the 2 labels belonged to a single cell.
For quantitation purposes nine sections from each brain
were evaluated covering the center of the lesion. The BrDU
labeling in these sections was visualized by horseradish
peroxidase conjugated streptavidin followed by reaction with
diaminobenzidine. Nuclei were counterstained with hemato-
xylin. The sections were observed using bright field micro-
scopy. The number and distribution of BrDU positive cells
were calculated by an observer blinded to the treatment group
of the animals.
Immunohistochemical detection of tyrosine nitration was
performed 2 and 6 days after grafting. The deparaffinized
sections were treated with 0.3% hydrogen peroxide for 15 min
to block endogenous peroxidase activity and then rinsed briefly
in 10 mM pH 7.4 phosphate buffered saline (PBS). Non-
specific binding was blocked by incubating the slides for 1 h
in PBS containing 2% goat serum. Mouse monoclonal anti-
nitrotyrosine antibody (Upstate Biotechnology, Lake Placid,
NY) and isotype-matched control antibody was applied in a
dilution of 1:200 for 1 h at room temperature. After extensive
washing (3x 10 min) with 0.25% Triton/PBS, immunoreactivity
was detected with a biotinylated horse anti-mouse secondary
antibody and the avidin-biotin-peroxidase complex (ABC)
both supplied in the Vector Elite kit (Vector Laboratories,
Burlingame, CA). Color was developed using Ni-DAB
substrate-kit  (Vector Laboratories, Burlingame, CA). Sections
were then counterstained with nuclear fast red, dehydrated
and mounted in Permount.
All drugs and chemicals were obtained from Sigma
Chemicals (St. Louis, MO), unless stated otherwise.
Statistics and data analysis. Data are presented as means ±
SEM, n represents the number of animals used. Statistics were
carried out using ANOVA or ANOVA for repeated measures
followed by Fisher's protected Least Significant Different test
for post-hoc comparisons. A p-value <0.05 was considered
significant.
Results
Cold lesion. The pre-cooled stamp caused a wedge-like
penetrating lesion which affected all layers of the cortex with
an average volume of 10.5±1.5 mm3. The lesion affected the
left forelimb motor cortex and resulted in a highly reproducible,
isolated motor deficit in the right forelimb (neurological score,
8.3±0.5 on a scale of 4 to 12).
Treatment of the animals with either the ONOO-
decomposition catalyst FP15 or the PARP inhibitor PJ34
failed to decrease the volume of the lesion (Fig. 1). However,
both treatment groups had a significantly higher neurological
score than the controls (control, 7.5±0.2; PJ34, 8.1±0.3, p<0.01;
FP15, 8.8±0.8, p<0.01) (Fig. 1).
Cold lesion followed by transplantation. Staining of the tissues
with the anti-nitrotyrosine antibody revealed that there is
intense ONOO- production in the lesioned brain during the
first days following transplantation (Fig. 2). ONOO- production
was most pronounced after 2 days and it was markedly
reduced on the 6th day. This finding indicated that the
ONOO- - PARP cascade induced damage occurs during the
first few days after grafting. No positive staining could be
seen in the isolated embryos proving that the ONOO- induced
damage occurred after grafting, not in the embryos (not
shown).
Histological evaluation of the transplanted brains was
carried out 6 days after grafting. BrDU positive transplanted
cells were found in each brain section, which contained the
lesion and no cells were found anywhere outside the affected
area or in the other hemisphere. The labeled cells were similar
in appearance to the surrounding host tissue.
Quantitative evaluation of the surviving graft was carried
out by counting the BrDU positive cells in the brain sections.
The number of surviving grafted cells was significantly
higher in the PJ34-treated group 6 days after transplantation
(Fig. 3). The neurological score of the PJ34-treated animals
was significantly improved compared to the untreated control
group. Interestingly, this improvement started as early as 1 day
after transplantation and was still pronounced after 6 days
(Fig. 3).
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The fate of the grafted cells. Immunohistochemical labeling
showed that some BrDU positive cells had the morphology
of astrocytes and expressed GFAP (Fig. 4). These cells were
mainly located in the penumbra and were similar in appearance
to the surrounding unlabeled astrocytes. Similarly, some BrDU
positive grafted cells expressed MBP, an oligodendrocyte
marker or neurofilament 68, a neuronal marker. However,
these other cell types were much fewer than the astrocytic
cells, typically 0 or 1 in a section (not shown). All the surviving
BrDU positive cells, which were found deeper in the lesion
had an undifferentiated phenotype and did not express lineage
specific markers. Three-dimensional reconstitution of the
triple-labeled cells confirmed that the BrDU positive nucleus
was enclosed by the lineage-specific labeled cytoplasm.
Discussion
The present study demonstrated the beneficial effect of PARP
inhibition on brain trauma and neural stem cell transplantation.
Treatment with a PARP inhibitor improved the neurological
score after the lesion, and increased it even further following
stem cell transplantation. High ONOO- production coincides
with the loss of the majority of the grafted cells, and inhibition
of the PARP activation cascade significantly increases the
number of surviving cells.
The present study found elevated ONOO- production
during the first few days after transplantation, and treatment
with a PARP inhibitor significantly improved the survival of
the graft. Other studies using various transplantation methods
agree that a dramatic loss of the transplanted cells occurs
during the first week of grafting (15). Improvement in graft
survival found in the present study may be the result of two
complimentary effects: the treatment may make the host
more receptive to the graft, or the treatment can have a direct
protective effect on the transplanted cells themselves. In the
present study we found that the PARP-inhibitor treated
animals exhibited better neurological scores than the controls
on the day of grafting, which may indicate better reception
on the host side. However, this treatment cannot achieve the
full survival of the graft and it is possible that combination
approaches, like free radical and oxidant scavenging plus
necrosis and apoptosis blockade, may be more effective.
The majority of the surviving cells, which were located in
the core of the lesion were still undifferentiated after 6 days.
However, most of the cells which were found in the penumbra
differentiated into astrocytes. During 6 days, these cells
migrated from the place of injection, differentiated to astro-
cytes, and dispersed evenly in the brain surrounding the
lesion core. This process indicates that there is a need for newly
formed astrocytes in the penumbra and the differentiation of
the multipotent cells is mainly restricted to the astrocytic
lineage.
The differentiation of stem or precursor cells in the brain
is largely dependent on growth factors (41). The local
concentration of the growth factor mixture determines the fate
of the multipotent cells, i.e. neuronal or glial differentiation.
The present study found that most of the differentiated grafted
cells had the phenotype of astrocytes. Recent studies indicated
the active role of these cells in the neuronal repair process by
the production of growth factors (42). It is possible, therefore,
that the newly formed glial cells are important in the
differentiation of the other, remaining stem cells.
A surprising finding in the present study is the significantly
better functional recovery of the PARP-inhibitor treated
animals compared to the untreated controls. This observation
is consistent with previous studies using other brain trauma or
stroke models (30,32). Similar to a previous study in traumatic
brain injury (32), the protective effect of PARP inhibition
could not be attributed to salvaging significant amounts of
lesioned tissue, and thus it may indicate that functional
improvement in some cases is not closely correlated to the
extent of brain damage. Transplantation of stem cells, which
readily differentiate into penumbral astrocytes improves
performance even further. These new astrocytes may help to
maintain the neurological function in the affected, but
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Figure 1. The effect of the inhibition of the ONOO- - PARP activation
cascade in cold lesion. A, shows respective brain slices stained with TTC
6 days after the lesion. B, shows the volume of the lesion. There was no
significant difference in lesion volume among the three treatment groups. C,
shows the neurological score of the animals 6 days after the lesion. Both the
PARP inhibitor PJ34 (n=12) and the ONOO- decomposition catalyst FP15
(n=4) improved the neurological score compared to the control group (n=11).
Values are expressed as mean ± SEM. The asterisks represent p<0.01 versus
control.
salvageable tissue by promoting regeneration with increased
growth factor production (43). This view is supported by a
study of Philips et al, in which significant functional recovery
was found after brain trauma, which was attributed to grafted
neural growth factor (NGF) overproducing cells (5).
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Figure 2. Nitrotyrosine formation during transplantation. A and C, show anti-nitrotyrosine immunohistochemistry performed 2 days after grafting. Note the
intense staining in the lesion area, especially close to the brain surface or in the penumbra. B and D, show nitrotyrosine staining 6 days after grafting. The
intensity of the staining is markedly reduced. Only the surface of the lesion shows significant tyrosine nitration.
Figure 3. The effect of PARP inhibition on the grafted cells. A, shows the
number of surviving transplanted cells 6 days after grafting. The animals
treated with PJ34 (n=6) had a significantly higher number of surviving cells
than the untreated controls (n=5). Nine sections were evaluated in each
animal. B, shows the neurological score of the animals on a scale of 4-12,
higher score represents better performance. One day after the cold lesion all
animals had a significant neurological deficit and there was no difference
between the treatment groups. Grafting was performed on day 0 following
which the animals treated with PJ34 (n=6) had a significantly better score
than the controls (n=5). *p<0.05. **p<0.01.
Figure 4. BrDU positive transplanted cells express the astrocyte-marker
GFAP. Transplanted cell nuclei are labeled with BrDU (green), while the
astrocyte-specific cytoplasmic marker GFAP is red. Four differentiated
astrocytes are shown, which are similar to other astrocytes in the vicinity.
Insert shows a BrDU positive astrocyte in high magnification.
We conclude that the ONOO- - PARP activation cascade
plays a pathogenetic role in brain trauma and regeneration.
Treatment with a PARP inhibitor may help to make the host
brain more receptive for neural stem cell grafting and can
promote rapid functional recovery. These results also suggest
that stem cell grafts are more likely to serve a supportive
function in the recovery process rather than simply ‘filling
the hole’. This view of neural stem cell grafting may promote
the design of novel therapeutic approaches, where early
neuroprotective therapy prepares the brain for the subsequent
transplantation surgery. This approach may ultimately lead to
an optimized grafting strategy, which utilizes a small number
of stem cells and yet significantly improves functional
recovery.
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